Furthermore, small-molecule tyrosine kinase inhibitors, lipid metabolism-targeting agents, and gene therapy are also being actively investigated (11).This review focuses on the latest advances in targeted therapies approved for ovarian cancer, particularly innovations in combination treatment strategies integrating anti-angiogenesis, PARP inhibition, and immunotherapy. The gene discussed is PARP1; the disease is ovarian carcinoma.